A retrospective study of advanced NSCLC across over 70 community sites in the US showed that only ~50% of patients were tested for ALK alterations during their cancer care [95], suggesting that advancements in liquid biopsies and testing are not translating to real-world practice. Here, ALK is linked to non-small cell lung carcinoma.